Where I see patients (2)
My reviews
Selected research
-
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN
-
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
Cancer drug resistance (Alhambra, Calif.)
-
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
The Lancet. Oncology
4.9